Last reviewed · How we verify
EXVIERA
EXVIERA is a direct-acting antiviral (DAA) combination therapy that inhibits hepatitis C virus (HCV) NS5A and NS5B proteins to prevent viral replication.
EXVIERA is a direct-acting antiviral (DAA) combination therapy that inhibits hepatitis C virus (HCV) NS5A and NS5B proteins to prevent viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1 and 4.
At a glance
| Generic name | EXVIERA |
|---|---|
| Also known as | Dasabuvir |
| Sponsor | HaEmek Medical Center, Israel |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5A, NS5B, NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
EXVIERA combines dasabuvir (NS5B inhibitor) with ombitasvir and paritaprevir (NS5A and NS3/4A inhibitors respectively) to target multiple sites of HCV replication. This multi-targeted approach achieves high cure rates across HCV genotypes with shorter treatment durations and improved tolerability compared to earlier interferon-based regimens.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotypes 1 and 4
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Elevated bilirubin
Key clinical trials
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (PHASE2, PHASE3)
- A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
- Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
- Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (PHASE4)
- eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXVIERA CI brief — competitive landscape report
- EXVIERA updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI